Month: December 2022

Rowbottom, Martin W. et al. published their research in Journal of Medicinal Chemistry in 2012 | CAS: 59669-59-9

3-(tert-Butyl)isoxazol-5-amine (cas: 59669-59-9) belongs to isoxazole derivatives. Isoxazoles also form the basis for a number of drugs, including the COX-2 inhibitor valdecoxib (Bextra) and a neurotransmitter agonist AMPA. Fe(CO)5 efficiently cleaves the N–O bond of fused isoxazolo-1,4-quinones to give the corresponding imines.All the common reducing reagents failed to open the isoxazole ring.Name: 3-(tert-Butyl)isoxazol-5-amine

Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E was written by Rowbottom, Martin W.;Faraoni, Raffaella;Chao, Qi;Campbell, Brian T.;Lai, Andiliy G.;Setti, Eduardo;Ezawa, Maiko;Sprankle, Kelly G.;Abraham, Sunny;Tran, Lan;Struss, Brian;Gibney, Michael;Armstrong, Robert C.;Gunawardane, Ruwanthi N.;Nepomuceno, Ronald R.;Valenta, Ianina;Hua, Helen;Gardner, Michael F.;Cramer, Merryl D.;Gitnick, Dana;Insko, Darren E.;Apuy, Julius L.;Jones-Bolin, Susan;Ghose, Arup K.;Herbertz, Torsten;Ator, Mark A.;Dorsey, Bruce D.;Ruggeri, Bruce;Williams, Michael;Bhagwat, Shripad;James, Joyce;Holladay, Mark W.. And the article was included in Journal of Medicinal Chemistry in 2012.Name: 3-(tert-Butyl)isoxazol-5-amine This article mentions the following:

The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell growth, differentiation, and survival. Expression of mutant BRAFV600E results in constitutive activation of the MAPK pathway, which can lead to uncontrolled cellular growth. Herein, we describe an SAR optimization campaign around a series of quinazoline derived BRAFV600E inhibitors. In particular, the bioisosteric replacement of a metabolically sensitive tert-Bu group with fluorinated alkyl moieties is described. This effort led directly to the identification of a clin. candidate 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496, I). CEP-32496 exhibits high potency against several BRAFV600E-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAFV600E vs. those containing wild-type BRAF. It also exhibits an excellent PK profile across multiple preclin. species. In addition, significant oral efficacy was observed in a 14-day BRAFV600E-dependent human Colo-205 tumor xenograft mouse model, upon dosing at 30 and 100 mg/kg BID. In the experiment, the researchers used many compounds, for example, 3-(tert-Butyl)isoxazol-5-amine (cas: 59669-59-9Name: 3-(tert-Butyl)isoxazol-5-amine).

3-(tert-Butyl)isoxazol-5-amine (cas: 59669-59-9) belongs to isoxazole derivatives. Isoxazoles also form the basis for a number of drugs, including the COX-2 inhibitor valdecoxib (Bextra) and a neurotransmitter agonist AMPA. Fe(CO)5 efficiently cleaves the N–O bond of fused isoxazolo-1,4-quinones to give the corresponding imines.All the common reducing reagents failed to open the isoxazole ring.Name: 3-(tert-Butyl)isoxazol-5-amine

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Frett, Brendan et al. published their research in MedChemComm in 2014 | CAS: 59669-59-9

3-(tert-Butyl)isoxazol-5-amine (cas: 59669-59-9) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. The electrophilic cyclization of various 2-alkynone O-methyl oximes with a wide range of substrates such as ICl, I2, Br2, PhSeBr, etc. provides a variety of 3,4,5-trisubstituted isoxazoles in good to excellent yields.Product Details of 59669-59-9

Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies was written by Frett, Brendan;McConnell, Nick;Wang, Yuanxiang;Xu, Zhigang;Ambrose, Andrew;Li, Hong-yu. And the article was included in MedChemComm in 2014.Product Details of 59669-59-9 This article mentions the following:

Trk receptors play a key role in the development and maintenance of neuronal networks. Recent evidence suggests that the Trk family, specifically TrkA, is an important driver for tumor growth, inflammatory and neuropathic pain, and chemoresistance. Through a computational screen, a novel Trk active pharmacophore was identified and a series of pyrazine-based inhibitors were developed, which potently inhibited TrkA. Inhibitors displayed the highest activity on TrkA when screened against a small, tyrosine kinase panel and also exhibited a non-linear SAR. Predicted binding modes of the inhibitors were examined, which identified exploitable regions for future development of more advanced inhibitors. In the experiment, the researchers used many compounds, for example, 3-(tert-Butyl)isoxazol-5-amine (cas: 59669-59-9Product Details of 59669-59-9).

3-(tert-Butyl)isoxazol-5-amine (cas: 59669-59-9) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. The electrophilic cyclization of various 2-alkynone O-methyl oximes with a wide range of substrates such as ICl, I2, Br2, PhSeBr, etc. provides a variety of 3,4,5-trisubstituted isoxazoles in good to excellent yields.Product Details of 59669-59-9

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Mityuk, Andrey P. et al. published their research in Synthesis in 2010 | CAS: 59669-59-9

3-(tert-Butyl)isoxazol-5-amine (cas: 59669-59-9) belongs to isoxazole derivatives. Isoxazoles also form the basis for a number of drugs, including the COX-2 inhibitor valdecoxib (Bextra) and a neurotransmitter agonist AMPA. Isoxazole can be synthesised via a variety of methods. Examples include via a 1,3-dipolar cycloaddition of nitrile oxides with alkynes.Recommanded Product: 59669-59-9

An efficient synthesis of fused 3-formylpyridines and 5-formylpyrimidines was written by Mityuk, Andrey P.;Kolodych, Sergey E.;Mytnyk, Sergey A.;Dmytriv, Yuri V.;Volochnyuk, Dmitriy M.;Mykhailiuk, Pavel K.;Tolmachev, Andrey A.. And the article was included in Synthesis in 2010.Recommanded Product: 59669-59-9 This article mentions the following:

Cyclization of 2-[(dimethylamino)methylene]-1,3-bis(dimethylimonio)propane diperchlorate, Me2NCH:C(CH:N+Me2)2.2ClO4–, with various amino heterocycles led to the formation of a series of fused heterocyclic systems containing a 3-formylpyridine or 5-formylpyrimidine unit. In the experiment, the researchers used many compounds, for example, 3-(tert-Butyl)isoxazol-5-amine (cas: 59669-59-9Recommanded Product: 59669-59-9).

3-(tert-Butyl)isoxazol-5-amine (cas: 59669-59-9) belongs to isoxazole derivatives. Isoxazoles also form the basis for a number of drugs, including the COX-2 inhibitor valdecoxib (Bextra) and a neurotransmitter agonist AMPA. Isoxazole can be synthesised via a variety of methods. Examples include via a 1,3-dipolar cycloaddition of nitrile oxides with alkynes.Recommanded Product: 59669-59-9

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Zhu, Bin’s team published research in Xiandai Zhongxiyi Jiehe Zazhi in 24 | CAS: 198470-85-8

Xiandai Zhongxiyi Jiehe Zazhi published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C10H2F12NiO4, Safety of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Zhu, Bin published the artcileStudy on the effect of parecoxib sodium on postoperative pain syndrome in patients after thoracotomy, Safety of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Xiandai Zhongxiyi Jiehe Zazhi (2015), 24(17), 1918-1919, database is CAplus.

The objective of this paper was to evaluate the effect of parecoxib sodium on postoperative pain syndrome in patients after thoracotomy. 96 Cases for thoracotomy were randomly and averagely divided into test group (giving parecoxib sodium and combined general and epidural anesthesia) and control group (giving physiol. saline and combined general and epidural anesthesia). The remifentanil dosage during thoracotomy, the dosage of opiates within 72 h after thoracotomy, adverse reaction incidence condition, pain incidence condition within 6 mo and pain duration in both group were compared. The morphine dosage within 72 h after thoracotomy in control group was (21.4±4.7) mg, while that in test group was 0 mg, and there was statistical difference (P<0.05). The incidence rates of gastrointestinal reaction and skin rash/itching in test group were lower than those in control group, and there was statistical difference (both P<0.05). The pain incidence within 6 mo and pain duration in test group were lower than those in control group, and there was statistical difference (both P<0.05). Parecoxib sodium could be used in thoracotomy, effectively reduce incidence of postoperative complications, and decrease the occurrence and duration of postoperative pain syndrome.

Xiandai Zhongxiyi Jiehe Zazhi published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C10H2F12NiO4, Safety of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Zhou, Yu-jing’s team published research in Hainan Yixueyuan Xuebao in 21 | CAS: 198470-85-8

Hainan Yixueyuan Xuebao published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C13H26N2, Product Details of C19H17N2NaO4S.

Zhou, Yu-jing published the artcileEffect of preemptive analgesia with parecoxib sodium on pain after laparoscope in gynecology department, Product Details of C19H17N2NaO4S, the publication is Hainan Yixueyuan Xuebao (2015), 21(10), 1422-1424, database is CAplus.

Objective: To observe the effect of preemptive analgesia with parecoxib sodium on pain after laparoscope in gynecol. department. Methods: A total of 100 cases with surgery under laparosocope, at stage ASA I-II, admitted from Jan. 2013 to Feb. 2014 were selected. They ere randomly divided into observation group and control group. Patients in observation group were treated with i.v. injection of parecoxib sodium 40 mg 30 min before surgery, and with i.v. injection of fentany1 citrate 1.0 μg/kg 30 min before the end of surgery. Patients in control group were treated with i.v. injection of parecoxib sodium 40 mg and fentany1 citrate 1.0 μg/kg 30 min before the end of surgery. The analgesia and sedative effect at 4, 8, 12 h after surgery were observed The addnl. dosage of fentany1 and the incidence of side effect were also observed Results: Analgesia score VAS at every time point and total dosage of fentanyl were significantly lower in observation group (P<0.05). There was no significant difference in Ramsay sedative score and incidence of side effect between two groups (P>0.05). Conclusions: Preemptive analgesia with parecoxib sodium can reduce the dosage, and is of exact analgesia effect. It is worthy clin. application.

Hainan Yixueyuan Xuebao published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C13H26N2, Product Details of C19H17N2NaO4S.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Yuan, Fen’s team published research in Xinjiang Yike Daxue Xuebao in 39 | CAS: 198470-85-8

Xinjiang Yike Daxue Xuebao published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C30H24BrCuN2P, Formula: C19H17N2NaO4S.

Yuan, Fen published the artcilePrevention and treatment of dezocine combined parecoxib sodium on of patients with postoperative hyperalgesia after remifentanil anesthesia, Formula: C19H17N2NaO4S, the publication is Xinjiang Yike Daxue Xuebao (2016), 39(7), 869-872, database is CAplus.

Objective To explore the prevention and treatment of dezocine combined parecoxib sodium on patients with postoperative hyperalgesia after remifentanil anesthesia. Methods 489 cases of patients treated with operation in our hospital from March 2014 to Dec. 2015 were divided into exptl. group (245 cases) and control group (244 cases) randomly. The exptl. group was administered parecoxib sodium before operation and intraoperative dezocine, and the control group were treated with single parecoxib sodium before operation. The time of extubation, recovery of spontaneous breathing and recovery of consciousness of the two groups after operation were observed The dynamic heart rates (HR), mean arterial pressure (MAP) and pain were recorded and/or evaluated before and after operation in two groups. Results The time of extubation, recovery of spontaneous breathing and recovery of consciousness of the exptl. group were significantly shorter than those of the control group, while the HR and MAP after operation of the exptl. group were significantly better than those of the control group; the pain scores of the exptl. group after operation were significantly better than those of the control group (P<0.01). The rate of adverse reactions of the exptl. group was 13.06%, while that of the control group was 12.70%, which was no significant difference between them (P>0.05). Conclusion The prevention and treatment of dezocine combined parecoxib sodium on patients with postoperative hyperalgesia after remifentanil anesthesia were remarkable with stable postoperative hemodynamics, which was worthy of application in clin.

Xinjiang Yike Daxue Xuebao published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C30H24BrCuN2P, Formula: C19H17N2NaO4S.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Wang, Ze-bo’s team published research in Xiandai Zhenduan Yu Zhiliao in 27 | CAS: 198470-85-8

Xiandai Zhenduan Yu Zhiliao published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C26H26N4O7, Computed Properties of 198470-85-8.

Wang, Ze-bo published the artcileApplication of parecoxib sodium combined with fentanyl in surgery of nucleus pulposus of lumbar intervertebral disc, Computed Properties of 198470-85-8, the publication is Xiandai Zhenduan Yu Zhiliao (2016), 27(10), 1801-1803, database is CAplus.

Objective: To analyze the effect of parecoxib sodium combined with fentanyl in surgery of nucleus pulposus of lumbar intervertebral disk, so as to provide reference for clin. anesthesia. Methods: A total of 78 patients undergoing surgery of nucleus pulposus of lumbar intervertebral disk in our hospital from July 2014 to Feb. 2015 were selected as the research subjects, and were divided into a study group and a control group, according to the time of admission. Patients in the study group took parecoxib sodium combined with fentanyl for analgesia, and patients in the control group took fentanyl for analgesia. The analgesia before anesthesia (T0), needle piercing the back skin (T1), disk fibrosis edge (T2), window opening (T3), nucleus pulposus removal (T4), and radiofrequency ablation time (T5) was analyzed. Results: At T0, there were no significant differences in MAP (mean arterial pressure), HR (heart rate) or SpO2 (blood oxygen saturation), and no significant difference in VAS scores (P > 0.05). At T1-T5, the MAP of the study group was significantly lower than that of the control group (P < 0.05). At T1-T5, the HR of the study group was significantly lower than that of the control group (P < 0.05), and the SpO2 of the two groups did not change significantly (P > 0.05). At T1-T5, the VAS score of the study group was significantly lower than that of the control group (P < 0.05). The incidence (15.4%) of addnl. drugs in the study group was significantly lower than that (35.9%) in the control group (P < 0.05). There were no adverse reactions such as nausea or lethargy in the two groups of patients during treatment and after surgery. Conclusion: The use of parecoxib sodium combined with fentanyl in patients undergoing surgery of nucleus pulposus of lumbar intervertebral disk has a good analgesic effect and can reduce the dosage of fentanyl, which has practical value.

Xiandai Zhenduan Yu Zhiliao published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C26H26N4O7, Computed Properties of 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Liang, Shujun’s team published research in Hebei Yixue in 21 | CAS: 198470-85-8

Hebei Yixue published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, SDS of cas: 198470-85-8.

Liang, Shujun published the artcileEffect of sequential celecoxib with parecoxib sodium on perioperative analgesia and joint function recovery of total hip replacement, SDS of cas: 198470-85-8, the publication is Hebei Yixue (2015), 21(11), 1869-1872, database is CAplus.

Objective: To observe and explore the analgesic effect of sequential celecoxib with parecoxib sodium during unilateral total hip arthroplasty (THR) during perioperative period, and to compare with the effect of tramadol. Methods: A total of 102 unilateral THR patients selected from 2011 to May 2014 were randomly divided into a study group (52 cases) and a control group (50 cases). In the study group, 40 mg parecoxib sodium was injected i.v. 30 min before anesthesia induction, and THR surgery was performed after routine anesthesia, analgesia pump was routinely used for analgesia for 2 days after surgery, and 40 mg parecoxib sodium was injected i.v. 3 h after surgery, 2 times/d, for consecutive days, and on the 3rd postoperative day, the celecoxib capsules were taken orally at 200 mg twice a day until discharged. In the control group, 100 mg tramadol injection was injected, and on the 3rd postoperative day, tramadol tablets were taken orally, and other analgesic regimens during the perioperative period were the same as the study group. The visual analog pain (VAS) score and passive active Harris hip score were compared in the perioperative resting state between the two groups. Adverse drug reactions were recorded during analgesia. Results: Within 24 h after operation, the number of analgesia pump compressions in the study group (10.2 ± 3.5) was significantly less than that in the control group (15.8 ± 5.5) (u = 6.108, P < 0.001). The VAS scores at 12 h, 24 h, 48 ??hours, 72 h, and 96 h in the study group were significantly lower than those in the control group (P < 0.05). The Harris hip scores at 7 and 14 days after surgery in both groups were significantly improved compared with those before surgery. The scores at 7 and 14 days after surgery in the study group were significantly higher than those in the control group (P < 0.05). The perioperative nausea, vomiting, dizziness, drowsiness, urinary retention and other adverse drug reactions in the study group were lower than those in the control group, without statistically significant difference (P > 0.05). Conclusion: Sequential celecoxib with parecoxib sodium during THR during perioperative period can significantly reduce the pain of patients, reduce the dose of opioids in the analgesia pump, and help patients to exercise hip function as soon as possible, and has low incidence of the adverse reactions compared with tramadol.

Hebei Yixue published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, SDS of cas: 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Li, Jun’s team published research in Jilin Yixue in 35 | CAS: 198470-85-8

Jilin Yixue published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Computed Properties of 198470-85-8.

Li, Jun published the artcileInfluences of parecoxib sodium on pulmonary oxygenation function in patients after valve replacement under cardiopulmonary bypass, Computed Properties of 198470-85-8, the publication is Jilin Yixue (2014), 35(34), 7638-7640, database is CAplus.

The influences of parecoxib sodium on pulmonary oxygenation function in patients after valve replacement under cardiopulmonary bypass (CPB) were evaluated. Sixty-three patients suffering from valve replacement under CPB were collected and divided into three groups: the control group (group I), parecoxib sodium 20 mg group (group II) and parecoxib sodium 40 mg group (group III). The changes of end-tidal CO2 pressure (PETCO2), arterial O2 concentration (CaO2), pulmonary alveolar-arterial O2 pressure (PA-aO2), oxygenation index (OI), spontaneous breathing frequency and ventilator assisted ventilation time in these patients were observed and compared. In group I, the levels of PA-aO2 and OI after surgery were significantly increased as compared before surgery. And the levels of PA-aO2 and OI in group III were significantly lower than those in group I and group II. The most stable spontaneous breathing frequency and the lowest incidence rate of dry/moist rales were observed in group III. It indicated that parecoxib sodium had protective effects on pulmonary injury and oxygenation function improvement in patients after valve replacement under CPB.

Jilin Yixue published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Computed Properties of 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Jurberg, Igor D.’s team published research in Chemistry – A European Journal in 23 | CAS: 1076-59-1

Chemistry – A European Journal published new progress about 1076-59-1. 1076-59-1 belongs to isoxazole, auxiliary class Oxazoline,Benzene,Ester, name is 3-Phenylisoxazol-5(2H)-one, and the molecular formula is C9H7NO2, Category: isoxazole.

Jurberg, Igor D. published the artcileAn Aminocatalyzed Stereoselective Strategy for the Formal α-Propargylation of Ketones, Category: isoxazole, the publication is Chemistry – A European Journal (2017), 23(41), 9716-9720, database is CAplus and MEDLINE.

A two-step reaction sequence is described for the asym. formal α-propargylation of ketones. This approach takes advantage of an aminocatalyzed conjugate addition of ketones to alkylidene isoxazol-5-ones, followed by a controlled nitrosative degradation event. The target compounds can be accessed in broad scope, in moderate to good yields, perfect diastereocontrol and good to excellent enantioselectivity.

Chemistry – A European Journal published new progress about 1076-59-1. 1076-59-1 belongs to isoxazole, auxiliary class Oxazoline,Benzene,Ester, name is 3-Phenylisoxazol-5(2H)-one, and the molecular formula is C9H7NO2, Category: isoxazole.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem